Evidence map›Paper›PMID 41269341›Full record

ArticleBreast cancer research and treatment2025

Mammary small cell neuroendocrine carcinomas that showed excellent pathologic response following etoposide-based neoadjuvant chemotherapy.

Phoebe M Hammer, Sheila Enamandram, Debra M Ikeda, Maggie M Lam, Irene L Wapnir, Erin D Chamberlain, Shagufta Shaheen, Jennifer L Caswell-Jin, Haruka Itakura, Gregory R Bean

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Phoebe M HammerDepartment of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305-5324, USA.
Sheila EnamandramDepartment of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Debra M IkedaDepartment of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Maggie M LamDepartment of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305-5324, USA.
Irene L WapnirDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Erin D ChamberlainDepartment of Medicine, Division of Oncology, University of California Los Angeles Medical Center, Los Angeles, CA, USA.
Shagufta ShaheenDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Jennifer L Caswell-JinDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Haruka ItakuraDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Gregory R BeanDepartment of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305-5324, USA. beang@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSmall cell neuroendocrine carcinoma (SCNEC) is a very rare, highly aggressive subtype of breast cancer. There are no standard recommendations for the management of mammary SCNEC, and the use and response to neoadjuvant chemotherapy are not well studied. Etoposide is an agent not included in guidelines for the management of breast cancer but traditionally used in the treatment of small cell carcinoma of the lung.

methodsWe searched for institutional and consultation cases of breast SCNEC and identified those treated with neoadjuvant chemotherapy. Clinical, pathologic, and genetic findings of two patients with SCNEC of the breast treated with etoposide are described. Additionally, we performed a literature review of all known cases of mammary SCNEC treated with neoadjuvant chemotherapy to date.

resultsThese two women were the sole patients who underwent neoadjuvant etoposide-based chemotherapy followed by surgery for breast SCNEC at our institution in the past 25 years. Both patients achieved excellent imaging and pathologic responses, with no evidence of residual carcinoma in the subsequent breast excisions.

conclusionEtoposide may be considered as a therapeutic option in the neoadjuvant setting of breast SCNEC. More reports on this very rare breast cancer subtype and response to treatment are needed.

Indexed as

Breast NeoplasmsCarcinoma, NeuroendocrineCarcinoma, Small CellEtoposideAdultAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantFemaleHumansMiddle AgedNeoadjuvant TherapyTreatment OutcomeEtoposideBreast cancerComplete pathologic responseEtoposideNeoadjuvant chemotherapySmall cell neuroendocrine carcinoma

Identifiers

PMID41269341

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.